The gateway effect is an economic phenomenon, not a pharmacological one. The seminal 1999 report by the US Institute of Medicine, commissioned by the White House Office of National Drug Control Policy, examined the gateway hypothesis rigorously and concluded that cannabis itself does not act as a biochemical gateway to harder drugs. The physiological mechanism by which cannabis consumption would trigger neurological dependency on opioids does not exist.

The true gateway is prohibition. When citizens are forced to purchase cannabis in the illicit market, they must interact with criminal syndicates whose profit margins are exponentially higher on heroin, methamphetamine, and synthetic cannabinoids. The criminal dealer does not compartmentalise their product range. The licensed dispensary does. In Colorado, Oregon, Canada, and every other regulated jurisdiction, there is no evidence that cannabis legalisation increased the uptake of harder drugs. The gateway disappeared when the illegal market was no longer the only point of access.

In Mauritius, the eradication programme documented in Chapter Three has driven cannabis prices to Rs 1,200 to Rs 3,000 per gram. The cheapest alternative is a Rs 100 synthetic dose. The helicopter created the gateway. The law sustains it.

This narrative deliberately conflates correlation with causation. Over the last sixty years, global cannabis consumption has expanded from a niche subculture to mainstream global use involving hundreds of millions of people. If cannabis actively caused schizophrenia as a pharmacological mechanism, global schizophrenia rates would have risen in direct proportion to rising consumption. The epidemiological record shows they have not. The global prevalence of schizophrenia has remained entirely flat, hovering at approximately 1% of the population for decades, across both the period of restricted use and the period of massively expanded use.

The peer-reviewed literature distinguishes carefully between causation and correlation. Heavy, high-THC cannabis use in adolescence may accelerate the onset of psychotic symptoms in individuals with a pre-existing, genetically determined vulnerability to psychosis. The plant does not create that vulnerability. A person with no genetic predisposition to schizophrenia does not develop it through cannabis consumption. This distinction is routinely collapsed in public discourse, converting a conditional risk factor for a small vulnerable population into a universal threat to all users.

The 1994 National Comorbidity Survey, authored by Anthony, Warner, and Kessler and published in Experimental and Clinical Psychopharmacology, established the definitive peer-reviewed baseline for comparative drug dependence rates. The methodology evaluated the probability that a person who tried a substance would develop a clinical dependency as defined by DSM diagnostic criteria.

The findings: tobacco produces clinical dependency in 32% of users. Cocaine in 17%. Alcohol in 15%. Cannabis in 9%. To criminalise a botanical plant with a 9% dependence profile whilst simultaneously protecting, marketing, and extracting excise tax from the tobacco industry, which addicts nearly a third of all users and kills 8 million people per year globally, is a legislative hypocrisy that no public health argument can rationalise. The comparison is never made in the policy discourse around cannabis because the moment it is made, the proportionality of the cannabis criminal penalty becomes impossible to defend.

Unregulated black markets do not check identification. Licensed dispensaries are legally required to. The empirical data from the most closely studied legalisation jurisdiction in the world directly contradicts the youth epidemic prediction. When Colorado became one of the first US states to legalise adult-use cannabis in 2014, prohibitionists predicted a catastrophic increase in youth consumption. The state commissioned the Healthy Kids Colorado Survey, the largest public health survey in Colorado's history, to track precisely this outcome.

Between 2013, the year before legalisation, and 2015, the year after, past-month cannabis use among Colorado high school students remained virtually flat at approximately 21%, a figure that was lower than the US national average of 22% for the same period. By bringing the market into the light, age-gating became a regulatory reality rather than an aspiration. The finding is replicated in subsequent Colorado survey data and in Canadian post-legalisation youth use data. Prohibition is, structurally, the only drug distribution system that allows an eleven-year-old to buy cannabis. The illegal dealer does not ask for identification. The licensed retailer faces prosecution if they fail to verify it.

The enforcement of cannabis laws is structurally engineered to target minority and working-class communities while affluent consumption remains largely undisturbed. The American Civil Liberties Union's landmark 2013 report, The War on Marijuana in Black and White, examined millions of cannabis arrests across every county in the United States using FBI Uniform Crime Report data and Census demographic data. The finding was unambiguous: despite statistically identical rates of cannabis use between white and Black Americans, Black citizens were 3.73 times more likely to be arrested for cannabis possession.

The disparity is not explained by differential use rates. It is explained by differential enforcement patterns: which neighbourhoods are policed, which communities are targeted, which individuals are stopped and searched. This enforcement architecture mirrors the Mauritian reality documented in Chapter Three of this edition. The Anti-Drug and Smuggling Unit and the Special Striking Team disproportionately target young Creole men from specific working-class neighbourhoods in Port Louis and its surroundings. Affluent cannabis consumption in the private residences of the professional class generates no provisional charges. The law is the same for everyone. The enforcement is not.

This claim, first engineered by Harry Anslinger in congressional testimony in 1937, contradicts both the neurobiology of cannabis and the historical record of the research that followed. Alcohol suppresses the prefrontal cortex and reduces impulse control, creating a pharmacological mechanism that is causally linked to domestic violence and violent assault. Cannabis modulates the brain's glutamate and GABA systems, inducing muscle relaxation and sedation rather than disinhibition. The neurochemistry of the two substances is directly opposed in their relationship to aggressive behaviour.

The research record confirms this distinction. The 1944 La Guardia Commission, after six years of clinical and sociological research in New York City, concluded explicitly that cannabis use does not alter the basic personality of the user and is not a determining factor in the commission of major crimes. The 1972 Shafer Commission, commissioned by President Nixon and delivered to a government that rejected its findings, reached identical conclusions. Anslinger's fabricated Gore File cases, presented to Congress in 1937 and examined in Chapter Three, were the empirical foundation of the violence claim. They were fabrications. The violence claim is their last surviving echo.

The human body contains an endocannabinoid system specifically designed to receive and process cannabinoid compounds, as documented in Chapter Two of this edition. Far from being a neurotoxin, cannabinoids are uniquely protective of neurological tissue. The endocannabinoid retrograde signalling mechanism, by which endocannabinoids travel backward across the synapse to reduce neurological overload, is the brain's primary homeostatic defence against excitotoxicity, the mechanism by which excessive neurological firing damages or kills neurons.

The US government's own patent confirms this. US Patent 6,630,507, granted in 2003 to the United States Department of Health and Human Services, and documented in detail in Chapter Three of this edition, explicitly states that cannabinoids act as powerful antioxidants and neuroprotectants capable of limiting neurological damage following stroke, trauma, and neurodegenerative diseases including Alzheimer's and Parkinson's. The same government that classifies cannabis as a dangerous narcotic with no medical value and no neuroprotective properties simultaneously owns the intellectual property rights on its neuroprotective properties. The brain damage narrative is not merely wrong. It is the inverse of the truth.